Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page / b, h) ?' ]4 z% T
% |, {+ ~) j1 d- X
8 _. m" B. B" q8 a/ Y4 dSub-category:
: C" x' R8 W K- ]( V, O) Y# uMolecular Targets
/ @3 y. o, Z9 R" H& Z7 S5 K0 m/ G1 f; u
8 d# V) G( u. J8 ]: B$ v
Category:
& O+ m1 }3 d: p% E+ j7 _Tumor Biology
# Q! y D" a( Q& t& D
; C! q" K; w7 P k6 G) W1 U& o, C: K
Meeting:
]: x, g( D& V) o# \/ h2011 ASCO Annual Meeting ! d- L O. ~8 r b1 s8 A/ C" w
3 f7 r3 V6 H2 K( k/ X
$ c7 Y, z \7 ]
Session Type and Session Title:
6 K: o. r; Z2 ]1 J" T" DPoster Discussion Session, Tumor Biology
" n' M, Y$ G% s- j. _
& ^4 h% y4 I) F+ X. }# V7 }# X5 E, `3 e5 i! C/ Y5 A
Abstract No:
3 |% i# x* t6 {% E+ J10517
: k3 M1 w; T6 M0 k k0 T
- `1 @9 `5 B, ~- y5 X* m# y
9 R6 \- |) J7 \6 W9 `: }Citation:
& U9 A3 W/ Z6 v7 k2 f7 Y- sJ Clin Oncol 29: 2011 (suppl; abstr 10517)
t; o) m4 ~2 g& b1 D M
" F# [& R& _) ~, n3 m* U) O Z5 @1 i
Author(s):
, G3 U3 {4 Y% OJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China - C( {7 o5 F' k, U/ }$ U/ Y# ^. G) h
4 k& r5 H n" E* d& ]. k; ?
$ t* k' L& k, l7 @ W
( K! V; k. P2 V5 }& @7 l
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
& ]8 U* X3 f" p6 m7 h6 t% N/ }. X$ q6 f! o# i: ]# n% f {' p+ Z7 Z
Abstract Disclosures5 ~+ ]5 F' B; t8 P$ s* [' W
: T5 P) t# `/ j5 p* S# _/ {Abstract:9 w3 H, y5 b% L+ \. ^
8 w: `! s, J( P: ^0 i2 B( s' g/ Q- Y: h2 L+ f# ]
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
$ l. A+ ?% z" W8 Q, {& R& m
$ v* n7 |: @4 V5 x8 }# H f# f 7 \, V Y0 p' v2 K
|
+ W3 c" N- A( d* `+ ^: m r
显身卡
